Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleni Galani

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Anticancer Research|August 15, 2002
Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patientsEleni Galani, Joseph Sgouros, Chariklia Petropoulou, et al.
Anticancer Research|August 19, 2007
Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology GroupDimosthenis V Skarlos, Maria Bai, Anna Goussia, et al.
Oncology|July 23, 2009
Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology GroupDimosthenis V Skarlos, Eleni Timotheadou, Eleni Galani, et al.
Journal of Colloid and Interface Science|December 19, 2022
Encapsulation of cannabidiol in oil-in-water nanoemulsions and nanoemulsion-filled hydrogels: A structure and biological assessment studySotiria Demisli, Eleni Galani, Maria Goulielmaki, et al.
Molecular and Clinical Oncology|February 20, 2016
Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemiaGiannis Mountzios, Gerasimos Aravantinos, Zoi Alexopoulou, et al.
Plos One|March 19, 2014
Differential expression of the insulin-like growth factor receptor among early breast cancer subtypesGiannis Mountzios, Dimitra Aivazi, Ioannis Kostopoulos, et al.
HGG Advances|December 26, 2025
Understanding Exceptional Response: The Role of MINDY1 SNP in CDK4/6 Inhibitor Therapy for ER-Positive, HER2-Negative Advanced Breast CancerEleni Balla, Yi Li, Zikun Zhou, et al.
Clinical Colorectal Cancer|September 21, 2013
The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximabAlexios Strimpakos, George Pentheroudakis, Vassiliki Kotoula, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2015
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patientsAnna Koumarianou, Georgia Karayannopoulou, Georgia Gourgioti, et al.
Plos One|May 14, 2015
Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trialGeorge Pentheroudakis, Georgia Raptou, Vassiliki Kotoula, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Anticancer Research|August 15, 2002
Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patientsEleni Galani, Joseph Sgouros, Chariklia Petropoulou, et al.
Anticancer Research|August 19, 2007
Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology GroupDimosthenis V Skarlos, Maria Bai, Anna Goussia, et al.
Oncology|July 23, 2009
Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology GroupDimosthenis V Skarlos, Eleni Timotheadou, Eleni Galani, et al.
Journal of Colloid and Interface Science|December 19, 2022
Encapsulation of cannabidiol in oil-in-water nanoemulsions and nanoemulsion-filled hydrogels: A structure and biological assessment studySotiria Demisli, Eleni Galani, Maria Goulielmaki, et al.
Molecular and Clinical Oncology|February 20, 2016
Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemiaGiannis Mountzios, Gerasimos Aravantinos, Zoi Alexopoulou, et al.
Plos One|March 19, 2014
Differential expression of the insulin-like growth factor receptor among early breast cancer subtypesGiannis Mountzios, Dimitra Aivazi, Ioannis Kostopoulos, et al.
HGG Advances|December 26, 2025
Understanding Exceptional Response: The Role of MINDY1 SNP in CDK4/6 Inhibitor Therapy for ER-Positive, HER2-Negative Advanced Breast CancerEleni Balla, Yi Li, Zikun Zhou, et al.
Clinical Colorectal Cancer|September 21, 2013
The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximabAlexios Strimpakos, George Pentheroudakis, Vassiliki Kotoula, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2015
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patientsAnna Koumarianou, Georgia Karayannopoulou, Georgia Gourgioti, et al.
Plos One|May 14, 2015
Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trialGeorge Pentheroudakis, Georgia Raptou, Vassiliki Kotoula, et al.
Pageof 3